Na, Peter J. http://orcid.org/0000-0003-3895-7417
De Angelis, Flavio
Nichter, Brandon
Wendt, Frank R. http://orcid.org/0000-0002-2108-6822
Krystal, John H. http://orcid.org/0000-0001-6952-1726
Southwick, Steven M.
Levey, Daniel F. http://orcid.org/0000-0001-8431-9569
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Polimanti, Renato http://orcid.org/0000-0003-0745-6046
Pietrzak, Robert H.
Funding for this research was provided by:
U.S. Department of Veterans Affairs (Internally funded by the VA National Center for PTSD, N/A)
Article History
Received: 20 June 2021
Revised: 30 September 2021
Accepted: 4 October 2021
First Online: 2 November 2021
Competing interests
: Drs. Gelernter and Polimanti are paid for their editorial work on the journal <i>Complex Psychiatry</i>. Dr. Krystal is a scientific advisor to Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc., Cadent Therapeutics (Clinical Advisory Board), PsychoGenics, Inc., Stanley Center for Psychiatric research at the Broad Institute of MIT and Harvard, Lohocla Research Corporation. J.H.K. owns stock and/or stock options in Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc., BlackThorn Therapeutics, Inc., Terran Biosciences, Inc. J.H.K. reports income <$10,000 per year from: AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation, Bionomics, Limited (Australia), Boehringer Ingelheim International, Concert Pharmaceuticals, Inc., Epiodyne, Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, L.E.K. Consulting, Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc. Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd. J.H.K. reports income >$10,000 per year from Biological Psychiatry (Editor). J.H.K. received the drug, Saracatinib from AstraZeneca and Mavoglurant from Novartis for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4] from AstraZeneca Pharmaceuticals. J.H.K. holds the following patents: (1) Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5447948.September 5, 1995; (2) Vladimir, Coric, Krystal, John H, Sanacora, Gerard—Glutamate Modulating Agents in the Treatment of Mental Disorders US Patent No. 8778979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695164: Filing Date: 09/05/2017; (3) Charney D, Krystal JH, Manji H, Matthew S, Zarate C—Intranasal Administration of Ketamine to Treat Depression United States Application No. 14/197767 filed on March 5, 2014; United States application or Patent Cooperation Treaty (PCT) International application No. 14/306382 filed on June 17, 2014; (4): Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Department of Veterans Affairs “Methods for Treating Suicidal Ideation”, Patent Application No. 14/197.767 filed on March 5, 2014 by Yale University Office of Cooperative Research; (5) Arias A, Petrakis I, Krystal JH.— Composition and methods to treat addiction. Provisional Use Patent Application no. 61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.; (6) Chekroud A, Gueorguieva R, Krystal JH. “Treatment Selection for Major Depressive Disorder” [filing date June 3, 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; (7) Gihyun, Yoon, Petrakis I, Krystal JH—Compounds, compositions and methods for treating or preventing depression and other diseases. US Provisional Patent Application No. 62/444552, filed on January 10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; and (8) Abdallah C, Krystal JH, Duman R, Sanacora G. Combination therapy for treating or preventing depression or other mood diseases. US Provisional Patent Application No. 62/719935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01. The remaining authors declare no competing interests.